Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Stifel Reiterates Buy Rating on Biogen (BIIB) Following Acquisition of HI-Bio
May 22, 2024 9:41 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $275.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "BIIB announced this morning plans to acquire Human Immunology Biosciences (HI-Bio) for $1.1B, with up to $650MM in potential milestone payments. This deal fits into... More
Piper Sandler Reiterates Overweight Rating on Biogen (BIIB) Following Acquisition of HI-Bio
May 22, 2024 9:33 AM EDTPiper Sandler analyst Christopher Raymond reiterated an Overweight rating and $335.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Remain OW rated on BIIB shares after announcement of the acquisition of HI-Bio for $1.15B up-front plus $650M in milestone payments. Bottom line... More
Biogen in up to $1.8 billion deal as rare diseases take center stage
May 22, 2024 7:37 AM EDT(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.
Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary... More
Biogen (BIIB) to Acquire Human Immunology Biosciences for $1.15B Upfront Plus Milestone Payments
May 22, 2024 7:31 AM EDTBiogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.
HI-Bios lead asset, felzartamab, is a fully... More
